Menopause and the opportunity for early cardio-renal-metabolic prevention

Abstract

The cardio-renal-metabolic syndrome is a systemic pathological entity that reflects complex interactions among obesity, diabetes, chronic kidney disease, and cardiovascular disease. In women, cardio-renal-metabolic risk increases markedly with age, and the menopausal transition functions as a key catalyst due to loss of the cardiometabolic protective effects of estrogen. The cardio-renal-metabolic syndrome is a systemic pathological entity that reflects complex interactions among obesity, diabetes, chronic kidney disease, and cardiovascular disease. In women, cardio-renal-metabolic risk increases markedly with age, and the menopausal transition functions as a key catalyst due to loss of the cardiometabolic protective effects of estrogen. This review examines the pathophysiologic mechanisms by which the menopausal transition promotes cardio-renal-metabolic and evaluates menopause as a critical window for preventive intervention. Declining estradiol levels during menopause drive redistribution of adipose tissue toward visceral depots, increased insulin resistance, endothelial dysfunction, and activation of the renin-angiotensin-aldosterone system. These changes promote progression from an absence of risk factors to more advanced clinical states. Timing-based hypotheses suggest that aggressive interventions initiated early in the menopausal transition confer maximal cardiometabolic benefit and may prevent irreversible end-organ damage. In conclusion, menopause is not merely a reproductive aging event but a crucial period for systemic risk modification that requires an integrated approach to interrupt the progression of cardio-renal-metabolic in women.